Skip to main content
. Author manuscript; available in PMC: 2009 Apr 17.
Published in final edited form as: Curr Treat Options Oncol. 2007 Feb;8(1):61–73. doi: 10.1007/s11864-007-0021-5

Table 4.

Clinical relevance of low-penetrance breast cancer susceptibility genes

Population frequency Hazard ratio (95% C.I) Population attributable risk (PAR)
TGFBR1*6A 0.5% homozygotes O.R. 2.69 (1.54–4.68) 4.9% (2.7%–7.2%) of all breast cancers
14.1% heterozygotes O.R. 1.23 (1.06–1.43)
CHEK2 0.5% heterozgotes O.R. 1.5 (1.2–1.8) Less than 0.5% of all breast cancers

J Clin Onc 57, 23:7743-7743; Am J Hum Genet 2004, 74:1175-82; Clin Cancer Res 2006, 12:4832-4835.